Marsh & McLennan Companies, Inc. (MRSH) Target Lowered by Barclays as AI Selloff Seen Overdone

We recently compiled a list of the 10 Oversold Insurance Stocks to Buy According to Analysts. Marsh & McLennan Companies, Inc. (NYSE:MRSH) is among the most oversold stocks.

TheFly reported on March 11 that Barclays adjusted its price target for MRSH to $209 from $210, while the firm maintained an Overweight rating on the stock. Barclays noted that the insurance brokerage sector has recently experienced a sharp selloff due to concerns over AI-related disruption, which the firm considers excessive. MRSH is positioned as a strong player that can profit from efficiency gains because current valuations are thought to already reflect slower growth while undervaluing the brokerage model’s durability and AI’s capacity to increase productivity and profitability.

Additionally, in a recent development, on March 2, the Marsh & McLennan Companies, Inc. (NYSE:MRSH) Agency unveiled Network Navigator. Employers may evaluate costs and network performance by region, specialty, and service type thanks to this exclusive healthcare pricing technology, which converts new price-transparency laws into comprehensive provider-level analytics.

By filling up the gaps in current network evaluation techniques that rely on insufficient or self-reported data, the tool is intended to assist employers in managing growing healthcare costs, optimizing plan selections, and directing staff to high-quality, economical care.

Marsh & McLennan Companies, Inc. (NYSE:MRSH) is a global professional services firm offering risk management, insurance brokerage, consulting, and advisory services to clients across industries worldwide.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.